Key Highlights
- DNL628 (OTV:MAPT) is in ongoing Phase 1b dosing, with clinical safety and biomarker data expected in 2027.
- Preclinical data showed DNL628 achieved broad, uniform central nervous system distribution of antisense oligonucleotides via intravenous delivery.
- DNL921 (ATV:Abeta) has a CTA/IND submitted in the first half of 2026, with a Phase 1/1b study planned and data expected in 2027.
- DNL921's TransportVehicle-enabled delivery is designed to bypass amyloid-laden large vessels, potentially mitigating ARIA risk seen with earlier anti-amyloid therapies.
Full Story
Why would a single company run two Alzheimer's programs that target the disease from almost opposite biological angles? Because Alzheimer's disease itself involves multiple, interacting pathological processes, and Denali Therapeutics appears to be betting that solving the brain-delivery problem, rather than picking a single target, is the more durable competitive advantage. Both DNL628 and DNL921 rely on the company's TransportVehicle platform, but they aim at entirely different disease mechanisms: tau pathology and amyloid pathology, respectively.
DNL628, also referred to as OTV:MAPT, targets tau, a protein that forms the neurofibrillary tangles long implicated in Alzheimer's disease progression, using an antisense oligonucleotide approach designed to reduce production of the tau protein at the genetic level. The program is currently in ongoing Phase 1b dosing, with clinical safety and biomarker data expected in 2027. What makes this program particularly notable is the delivery mechanism behind it. Recently disclosed preclinical research demonstrated that Denali's Oligonucleotide TransportVehicle achieved broad and uniform central nervous system distribution of antisense oligonucleotides, including reaching deeper brain structures, when administered intravenously, a meaningful advance compared with intrathecally delivered therapy, which requires direct spinal injection and often produces less uniform distribution throughout the brain.
That delivery distinction matters enormously in practice. Intrathecal administration, while capable of delivering therapeutic payloads to the central nervous system, is invasive, requires specialized clinical settings, and can be a significant burden for patients requiring repeated dosing over long treatment courses. An intravenous approach capable of achieving comparable or superior brain distribution would represent a substantial improvement in patient convenience and access, potentially widening the population of patients and clinical settings where such a therapy could realistically be administered.
DNL921, known as ATV:Abeta, takes a different biological target entirely: amyloid-beta, the protein fragment that aggregates into the plaques historically most associated with Alzheimer's disease. This program is earlier in development, with a Clinical Trial Application or Investigational New Drug submission completed in the first half of 2026, and a Phase 1/1b study planned with data expected in 2027. What differentiates DNL921's approach is a specific solution to one of anti-amyloid therapy's most persistent safety challenges: ARIA, or amyloid-related imaging abnormalities, a category of brain swelling and microhemorrhage side effects that has troubled earlier-generation anti-amyloid antibody therapies.
Denali's preclinical findings suggest that TransportVehicle-enabled delivery of this immunotherapy can bypass amyloid-laden large vessels by traveling through smaller capillaries instead, a targeted strategy specifically designed to reduce the vascular-related side effects that have limited the usability and dosing flexibility of earlier anti-amyloid treatments. If this approach holds up in human trials, it could meaningfully expand the population of Alzheimer's patients eligible for anti-amyloid treatment, including patients whose vascular risk profile might currently preclude them from safely receiving existing approved anti-amyloid therapies.
Taken together, these two programs reveal Denali's broader strategic thesis: rather than betting the company's Alzheimer's franchise entirely on a single biological target, they're using a shared delivery technology platform, TransportVehicle, to pursue both major pathological drivers of the disease simultaneously, tau and amyloid, while specifically engineering each program's delivery approach to solve that target's most persistent clinical challenge, whether that's achieving uniform brain distribution for tau-targeting oligonucleotides or minimizing vascular side effects for amyloid-targeting immunotherapy. With both programs pointing toward 2027 data, Denali has set up a period where its underlying delivery platform thesis will face real clinical validation across two distinct fronts of Alzheimer's disease at once.






Please wait processing your request...